Literature DB >> 23945432

[Severe bronchial asthma].

P Toutenhoofd1, J S van der Zee.   

Abstract

The term 'difficult-to-treat asthma' indicates that the asthma is not sufficiently controlled despite prescription of high doses of asthma medication. The term 'severe asthma' is used when the asthma is still insufficiently controlled after exclusion or treatment of any complicating factors; an important complicating factor is poor compliance. Recent studies have focused on the heterogeneous character of asthma and on the definition of specific phenotypes, with the aim of developing phenotype-specific treatments. Treatment options for severe asthma are only partly evidence based. The decision to implement additional therapy for severe asthma depends on the individual patient, the asthma phenotype, and the adverse-event profile of the treatment. Many of the additional therapies should be given as a trial treatment under strict control, especially when efficacy has not been convincingly scientifically proven.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23945432

Source DB:  PubMed          Journal:  Ned Tijdschr Geneeskd        ISSN: 0028-2162


  1 in total

1.  Substance P promotes the progression of bronchial asthma through activating the PI3K/AKT/NF-κB pathway mediated cellular inflammation and pyroptotic cell death in bronchial epithelial cells.

Authors:  Miao Li; Xiao Zhong; Wen-Ting Xu
Journal:  Cell Cycle       Date:  2022-06-26       Impact factor: 5.173

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.